Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug;103(8):2827-2836.
doi: 10.1007/s00277-024-05870-1. Epub 2024 Jul 6.

WT1 gene mutations impact post-transplant relapse in myelodysplastic syndrome with excess blasts 2 patients

Wenwen Guo  1   2 , Haixiao Zhang  1   2 , Mingyang Wang  1   2 , Yawei Zheng  1   2 , Yigeng Cao  1   2 , Xiaoyu Zhang  1   2 , Weihua Zhai  1   2 , Rongli Zhang  1   2 , Donglin Yang  1   2 , Jialin Wei  1   2 , Yi He  1   2 , Qiaoling Ma  1   2 , Yonghui Xia  1   2 , Aiming Pang  1   2 , Sizhou Feng  1   2 , Mingzhe Han  1   2 , Erlie Jiang  3   4
Affiliations

WT1 gene mutations impact post-transplant relapse in myelodysplastic syndrome with excess blasts 2 patients

Wenwen Guo et al. Ann Hematol. 2024 Aug.

Abstract

Wilms tumor 1 (WT1) gene mutations are infrequent in myelodysplastic syndrome (MDS), but MDS with WT1 mutations (WT1mut) is considered high risk for acute myeloid leukemia (AML) transformation. The influence of WT1 mutations in patients with MDS after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is unclear. We performed a retrospective analysis of 136 MDS with excess blasts 2 (MDS-EB2) patients with available WT1 status who underwent their first allo-HSCT between 2017 and 2022 in our center. There were 20 (20/136, 15%) cases in the WT1mut group and 116 (116/136, 85%) cases in the WT1 wild-type (WT1wt) group. WT1mut patients had a higher 2-year cumulative incidence of relapse (CIR) than WT1wt cases (26.2% vs. 9.4%, p = 0.037) after allo-HSCT. Multivariate analysis of relapse showed that WT1 mutations (HR, 6.0; p = 0.002), TP53 mutations (HR, 4.2; p = 0.021), and ≥ 5% blasts in bone marrow (BM) at transplantation (HR, 6.6; p = 0.004) were independent risk factors for relapse. Patients were stratified into three groups according to the risk factors. Two-year CIR differed significantly in high-, intermediate-, and low-risk groups (31.8%, 11.6%, and 0%, respectively). Hence, WT1 mutations may be related to post-transplant relapse in patients with MDS-EB2, which warrants further study.

Keywords: Allogeneic hematopoietic stem cell transplantation; Mutations; Myelodysplastic syndrome; WT1.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Ariyaratana S, Loeb DM (2007) The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med 9(14):1–17 - DOI - PubMed
    1. Rautenberg C, Germing U, Pechtel S et al (2019) Prognostic impact of peripheral blood WT1-mRNA expression in patients with MDS. Blood Cancer J 9(11):86 - DOI - PubMed - PMC
    1. Rautenberg C, Lauseker M, Kaivers J et al (2021) Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1-mRNA expression in patients with AML and MDS. Eur J Haematol 107(2):283–292 - DOI - PubMed
    1. Hou HA, Huang TC, Lin LI et al (2010) WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Blood 115(25):5222–5231 - DOI - PubMed
    1. Niktoreh N, Weber L, Walter C et al (2023) Understanding WT1 alterations and expression profiles in hematological malignancies. Cancers (Basel) 15(13):3491. https://doi.org/10.3390/cancers15133491

LinkOut - more resources